Renalytix Plc emerged among the strongest gainers after renewed investor interest in healthcare technology companies with commercial-stage diagnostic platforms.
RUA Life Sciences Plc has returned to investors' watchlists after gaining almost9%, making it one of the stronger-performing healthcare companies on AIM during the trading session.
Genus plc was one of today's stronger-performing FTSE-listed healthcare and biotechnology companies after its shares gained approximately5.31%, extending investor interest following several positive business developments.
Agronomics was among the notable gainers after renewed investor interest in companies exposed to the rapidly evolving cellular agriculture and cultivated food industry.
The US generics industry has faced persistent pricing pressure in recent years, as increased competition among manufacturers and consolidated purchasing power among distributors and pharmacy benefit managers have weighed on average selling prices across many product categories.
The rise in Syncona Limited (LSE:SYNC) today appears to be driven by renewed investor optimism toward biotechnology innovation and life sciences investment more broadly. As a company whose value is closely linked to its underlying portfolio of biotech businesses, positive sentiment across the broader …
Kooth's business is built around free, anonymous online counselling and peer-support services commissioned by health systems rather than sold to individual consumers. The central story right now: a business that grew explosively through US public-health contracts, then recorded a revenue and margin pause in …
The company announced today that it has dosed the first patient in its POLB 001 TOPICAL clinical trial, testing the drug as a preventative for cytokine release syndrome in multiple myeloma patients receiving a cancer immunotherapy.
For investors, Tivicay matters less as a single product line and more as the active substance that anchors a broader dolutegravir portfolio, including the two-drug regimen Dovato. Following a January 2026 agreement completed around April 2026, GSK retains a 78.3% economic interest in ViiV, …
The central question for investors is what this twice-yearly model could mean commercially. The theory is straightforward: fewer clinic visits and fewer injections may appeal to patients and prescribers. Depemokimab is approved for severe or eosinophilic asthma in adults and adolescents aged 12 and …